Hatzipanagiotou, Maria Eleni and Pigerl, Miriam and Gerken, Michael and Raepple, Sophie and Zeltner, Verena and Hetterich, Madeleine and Ugocsai, Peter and Fernandez-Pacheco, Miriam and Inwald, Elisabeth Christine and Klinkhammer-Schalke, Monika and Ortmann, Olaf and Seitz, Stephan (2023) Does timing of neoadjuvant chemotherapy influence the prognosis in patients with early triple negative breast cancer? JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 149 (13). pp. 11941-11950. ISSN 0171-5216, 1432-1335
Full text not available from this repository. (Request a copy)Abstract
PurposeFor patients with triple negative breast cancer (TNBC), the optimal time to initiate neoadjuvant chemotherapy (TTNC) is unknown. This study evaluates the association between TTNC and survival in patients with early TNBC.MethodsA retrospective study using data from of a cohort of TNBC patients diagnosed between January 1, 2010 to December 31, 2018 registered in the Tumor Centre Regensburg was performed. Data included demographics, pathology, treatment, recurrence, and survival. Interval to treatment was defined as days from pathology diagnosis of TNBC to first dose of neoadjuvant chemotherapy (NACT). The Kaplan-Meier and Cox regression methods were used to evaluate the impact of TTNC on overall survival (OS) and 5 year OS.ResultsA total of 270 patients were included. Median follow up was 3.5 years. The 5-year OS estimates according to TTNC were 77.4%, 66.9%, 82.3%, 80.6%, 88.3%, 58.3%, 71.1% and 66.7% in patients who received NACT within 0-14, 15-21, 22-28, 29-35, 36-42, 43-49, 50-56 and > 56 days after diagnosis. Patients who received systemic therapy early had the highest estimated mean OS of 8.4 years, while patients who received systemic therapy after more than 56 days survived an estimated 3.3 years.ConclusionThe optimal time interval between diagnosis and NACT remains to be determined. However, starting NACT more than 42 days after diagnosis of TNBC seems to reduce survival. Therefore, it is strongly recommended to carry out the treatment in a certified breast center with appropriate structures, in order to enable an adequate and timely care.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ADJUVANT CHEMOTHERAPY; OUTCOMES; IMPACT; TIME; INITIATION; SURVIVAL; SURGERY; THERAPY; Time to systemic therapy; Triple negative breast cancer; Neoadjuvant chemotherapy; Clinical cancer registry data |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde) Medicine > Zentren des Universitätsklinikums Regensburg > Tumorzentrum e.V. |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 08 Mar 2024 11:25 |
| Last Modified: | 08 Mar 2024 11:25 |
| URI: | https://pred.uni-regensburg.de/id/eprint/59146 |
Actions (login required)
 |
View Item |
